The present invention relates to neuromodulation systems, and more particularly, to neuromodulation system utilizing electrical pulse trains.
Implantable neuromodulation systems have proven therapeutic in a wide variety of diseases and disorders. Pacemakers and Implantable Cardiac Defibrillators (ICDs) have proven highly effective in the treatment of a number of cardiac conditions (e.g., arrhythmias). Spinal Cord Stimulation (SCS) systems have long been accepted as a therapeutic modality for the treatment of chronic pain syndromes, and the application of tissue stimulation has begun to expand to additional applications such as angina pectoralis and incontinence. Deep Brain Stimulation (DBS) has also been applied therapeutically for well over a decade for the treatment of refractory chronic pain syndromes, and DBS has also recently been applied in additional areas such as movement disorders and epilepsy. Further, in recent investigations, Peripheral Nerve Stimulation (PNS) systems have demonstrated efficacy in the treatment of chronic pain syndromes and incontinence, and a number of additional applications are currently under investigation. Furthermore, Functional Electrical Stimulation (FES) systems, such as the Freehand system by NeuroControl (Cleveland, Ohio), have been applied to restore some functionality to paralyzed extremities in spinal cord injury patients.
These implantable neuromodulation systems typically include one or more electrode carrying modulation leads, which are implanted at the desired stimulation site, and a neuromodulator (e.g., an implantable pulse generator (IPG)) implanted remotely from the stimulation site, but coupled either directly to the neuromodulation lead(s) or indirectly to the neuromodulation lead(s) via a lead extension. The neuromodulation system may further comprise a handheld patient programmer to remotely instruct the neuromodulator to generate electrical stimulation pulses in accordance with selected stimulation parameters. The handheld programmer in the form of a remote control (RC) may, itself, be programmed by a clinician, for example, by using a clinician's programmer (CP), which typically includes a general purpose computer, such as a laptop, with a programming software package installed thereon.
Electrical modulation energy may be delivered from the neuromodulator to the electrodes in the form of a pulsed electrical waveform. Thus, modulation energy may be controllably delivered to the electrodes to modulate neural tissue. The combination of electrodes used to deliver electrical pulses to the targeted tissue constitutes an electrode combination, with the electrodes capable of being selectively programmed to act as anodes (positive), cathodes (negative), or left off (zero). In other words, an electrode combination represents the polarity being positive, negative, or zero. Other parameters that may be controlled or varied include the amplitude, duration, and rate of the electrical pulses provided through the electrode array. Each electrode combination, along with the electrical pulse parameters, can be referred to as a “neuromodulation parameter set.”
Of course, neuromodulators are active devices requiring energy for operation, and thus, the neurostimulation system may oftentimes includes an external charger to recharge a neuromodulator, so that a surgical procedure to replace a power depleted neuromodulator can be avoided. To wirelessly convey energy between the external charger and the implanted neuromodulator, the charger typically includes an alternating current (AC) charging coil that supplies energy to a similar charging coil located in or on the neurostimulation device. The energy received by the charging coil located on the neuromodulator can then be used to directly power the electronic componentry contained within the neuromodulator, or can be stored in a rechargeable battery within the neuromodulator, which can then be used to power the electronic componentry on-demand.
In the context of an SCS procedure, one or more leads are introduced through the patient's back into the epidural space, such that the electrodes carried by the leads are arranged in a desired pattern and spacing to create an electrode array. After proper placement of the leads at the target area of the spinal cord, the leads are anchored in place at an exit site to prevent movement of the leads. To facilitate the location of the neuromodulator away from the exit point of the leads, lead extensions are sometimes used. The leads, or the lead extensions, are then connected to the IPG, which can then be operated to generate electrical pulses that are delivered, through the electrodes, to the targeted spinal cord tissue. The modulation, and in the conventional case, the stimulation, creates the sensation known as paresthesia, which can be characterized as an alternative sensation that replaces the pain signals sensed by the patient. The efficacy of SCS is related to the ability to modulate the spinal cord tissue corresponding to evoked paresthesia in the region of the body where the patient experiences pain. Thus, the working clinical paradigm is that achievement of an effective result from SCS depends on the neuromodulation lead or leads being placed in a location (both longitudinal and lateral) relative to the spinal tissue such that the electrical modulation will induce paresthesia located in approximately the same place in the patient's body as the pain (i.e., the target of treatment).
Conventional neuromodulation therapies employ electrical stimulation pulse trains at low- to mid-frequencies (e.g., less than 1500 Hz) to efficiently induce desired firing rate of action potentials from electrical pulses (e.g., one pulse can induce a burst of action potentials, or multiple pulses may be temporally integrated to induce on action potential). Such stimulation pulse trains are usually tonic (i.e., the pulse amplitude, pulse rate, and pulse width are fixed). However, neuron response is a dynamic time course that can vary with the sequential stimulation, thereby limiting the volume of neural tissue that may be consistently stimulated. Furthermore, it is known that neural tissue may accommodate, adapt, and/or habituate to a continuous tonic input, resulting in a diminished neural response over time.
Recently, high frequency modulation (e.g., 1.5 KHz-50 KHz), which has been increasingly attractive in neuromodulation for pain management, is employed to block naturally occurring action potentials within neural fibers or otherwise disrupt the action potentials within the neural fibers. Although the underlying mechanisms of high frequency modulation for pain reduction are yet unclear, it has been hypothesized that there are many mechanisms that potentially play a role in reducing pain, including the depletion of neurotransmitter during the sustained modulation, desynchronized firing of multiple neurons, and generation of stochastic noise in neuronal signal transmission or lesioning of pain information. One disadvantage of high-frequency pulsed electrical energy is that it consumes an excessive amount of energy, thereby requiring the neuromodulator device to be charged more often.
Furthermore, although certain conventional stimulation parameters (e.g., pulse amplitude, pulse frequency, and pulse width) of the pulsed electrical energy, whether delivered at a low-, mid-, or high-frequency, can be varied to optimize the therapy, it may be desirable to allow the user to vary other characteristics of the pulsed electrical energy in order to further tailor the pulsed electrical energy to the volume of neural tissue to be modulated.
There, thus, remains an improved technique for delivering pulsed electrical energy to a patient.
In accordance with a first aspect of the present inventions, a neuromodulation system comprises a plurality of electrical terminals configured for being respectively coupled to a plurality of electrodes, a user interface configured for receiving input from a user that defines a shape of a modulating signal, and neuromodulation output circuitry configured for outputting an electrical pulse train to the plurality of electrical terminals. The neuromodulation system further comprises pulse train modulation circuitry configured for modulating the electrical pulse train in accordance with the defined shape of the modulating signal. In one embodiment, one of a pulse amplitude, a pulse rate, and a pulse duration of the electrical pulse train is modulated by the amplitude of the modulating signal. In another embodiment, the user input comprises a selection of one of a plurality of different predefined shapes of the modulating signal (e.g., at least two of a sinusoidal wave, a triangular wave, and a ramp wave). In still another embodiment, the user interface is configured for receiving another input from the user selecting an electrical pulse parameter of the electrical pulse train to be modulated, and the pulse train modulation circuitry is configured for modulating the selected electrical pulse parameter of the electrical pulse train in accordance with the defined shape of the modulating signal. The neuromodulation system may further comprise a casing containing the plurality of electrical terminals, the user interface, the neuromodulation output circuitry, and the electrical pulse modulation circuitry.
In accordance with a second aspect of the present inventions, a neuromodulation system comprises a plurality of electrical terminals configured for being respectively coupled to a plurality of electrodes, a user interface configured for receiving an input from a user selecting one of a plurality of different electrical pulse parameters for an electrical pulse train (e.g., at least two of a sinusoidal wave, a triangular wave, and a ramp wave), and neuromodulation output circuitry configured for outputting the electrical pulse train to the plurality of electrical terminals. The neuromodulation system further comprises pulse train modulation circuitry configured for modulating the selected electrical pulse parameter of the electrical pulse train. The neuromodulation system may further comprise a casing containing the plurality of electrical terminals, the user interface, the neuromodulation output circuitry, and the electrical pulse modulation circuitry.
In accordance with a third aspect of the present inventions, a neuromodulation system comprises a plurality of electrical terminals configured for being respectively coupled to a plurality of electrodes, neuromodulation output circuitry configured for outputting an electrical pulse train to the plurality of electrical terminals, and pulse train modulation circuitry configured for modulating a pulse rate of the electrical pulse train in accordance with a determinate modulating signal. The neuromodulation system may optionally comprise a user interface configured for receiving an input from a user defining a characteristic of the modulating signal. In one embodiment, the characteristic of the modulating signal is a shape of the modulating signal. In this case, the user input may comprise a selection of one of a plurality of different predefined shapes of the modulating signal (e.g., at least two of a sinusoidal wave, a triangular wave, and a ramp wave. The neuromodulation system may further comprise a casing containing the plurality of electrical terminals, the neuromodulation output circuitry, and the electrical pulse modulation circuitry.
In accordance with a fourth aspect of the present inventions, a neuromodulation system comprises a plurality of electrical terminals configured for being respectively coupled to a plurality of electrodes, neuromodulation output circuitry configured for outputting an electrical pulse train to the plurality of electrical terminals, and pulse train modulation circuitry configured for modulating a pulse duration of the electrical pulse train in accordance with a determinate modulating signal. The neuromodulation system may optionally comprise a user interface configured for receiving an input from a user defining a characteristic of the modulating signal. In one embodiment, the characteristic of the modulating signal is a shape of the modulating signal. In this case, the user input may comprise a selection of one of a plurality of different predefined shapes of the modulating signal (e.g., at least two of a sinusoidal wave, a triangular wave, and a ramp wave. The neuromodulation system may further comprise a casing containing the plurality of electrical terminals, the neuromodulation output circuitry, and the electrical pulse modulation circuitry.
Other and further aspects and features of the invention will be evident from reading the following detailed description of the preferred embodiments, which are intended to illustrate, not limit, the invention.
The drawings illustrate the design and utility of preferred embodiments of the present invention, in which similar elements are referred to by common reference numerals. In order to better appreciate how the above-recited and other advantages and objects of the present inventions are obtained, a more particular description of the present inventions briefly described above will be rendered by reference to specific embodiments thereof, which are illustrated in the accompanying drawings. Understanding that these drawings depict only typical embodiments of the invention and are not therefore to be considered limiting of its scope, the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:
The description that follows relates to a spinal cord modulation (SCM) system. However, it is to be understood that while the invention lends itself well to applications in spinal cord modulation, the invention, in its broadest aspects, may not be so limited. Rather, the invention may be used with any type of implantable electrical circuitry used to stimulate tissue. For example, the present invention may be used as part of a pacemaker, a defibrillator, a cochlear stimulator, a retinal stimulator, a stimulator configured to produce coordinated limb movement, a cortical stimulator, a deep brain stimulator, peripheral nerve stimulator, microstimulator, or in any other neurostimulator configured to treat urinary incontinence, sleep apnea, shoulder sublaxation, headache, etc.
Turning first to
The IPG 14 is physically connected via one or more percutaneous lead extensions 24 to the neuromodulation leads 12, which carry a plurality of electrodes 26 arranged in an array. In the illustrated embodiment, the neuromodulation leads 12 are percutaneous leads, and to this end, the electrodes 26 may be arranged in-line along the neuromodulation leads 12. In alternative embodiments, the electrodes 26 may be arranged in a two-dimensional pattern on a single paddle lead. As will be described in further detail below, the IPG 14 includes pulse generation circuitry that delivers electrical modulation energy in the form of a pulsed electrical waveform (i.e., a temporal series of electrical pulses) to the electrode array 26 in accordance with a set of neuromodulation parameters.
The ETM 20 may also be physically connected via the percutaneous lead extensions 28 and external cable 30 to the neuromodulation leads 12. The ETM 20, which has similar pulse generation circuitry as the IPG 14, also delivers electrical modulation energy in the form of a pulse electrical waveform to the electrode array 26 accordance with a set of neuromodulation parameters. The major difference between the ETM 20 and the IPG 14 is that the ETM 20 is a non-implantable device that is used on a trial basis after the neuromodulation leads 12 have been implanted and prior to implantation of the IPG 14, to test the responsiveness of the stimulation that is to be provided. Thus, any functions described herein with respect to the IPG 14 can likewise be performed with respect to the ETM 20.
The RC 16 may be used to telemetrically control the ETM 20 via a bi-directional RF communications link 32. Once the IPG 14 and modulation leads 12 are implanted, the RC 16 may be used to telemetrically control the IPG 14 via a bi-directional RF communications link 34. Such control allows the IPG 14 to be turned on or off and to be programmed with different neuromodulation parameter sets. The IPG 14 may also be operated to modify the programmed neuromodulation parameters to actively control the characteristics of the electrical modulation energy output by the IPG 14. As will be described in further detail below, the CP 18 provides clinician detailed neuromodulation parameters for programming the IPG 14 and ETM 20 in the operating room and in follow-up sessions.
The CP 18 may perform this function by indirectly communicating with the IPG 14 or ETM 20, through the RC 16, via an IR communications link 36. Alternatively, the CP 18 may directly communicate with the IPG 14 or ETM 20 via an RF communications link (not shown). The clinician detailed neuromodulation parameters provided by the CP 18 are also used to program the RC 16, so that the neuromodulation parameters can be subsequently modified by operation of the RC 16 in a stand-alone mode (i.e., without the assistance of the CP 18).
The external charger 22 is a portable device used to transcutaneously charge the IPG 14 via an inductive link 38. For purposes of brevity, the details of the external charger 22 will not be described herein. Once the IPG 14 has been programmed, and its power source has been charged by the external charger 22 or otherwise replenished, the IPG 14 may function as programmed without the RC 16 or CP 18 being present.
For purposes of brevity, the details of the ETM 20 and external charger 22 will not be described herein. Details of exemplary embodiments of these devices are disclosed in U.S. Pat. No. 6,895,280, which is expressly incorporated herein by reference.
As shown in
Referring now to
As will be described in further detail below, the IPG 14 includes a battery and pulse generation circuitry that delivers the electrical modulation energy in the form of one or more electrical pulse trains to the electrode array 26 in accordance with a set of neuromodulation parameters programmed into the IPG 14. Such neuromodulation parameters may comprise electrode combinations, which define the electrodes that are activated as anodes (positive), cathodes (negative), and turned off (zero), percentage of modulation energy assigned to each electrode (fractionalized electrode configurations), and electrical pulse parameters, which define the pulse amplitude (measured in milliamps or volts depending on whether the IPG 14 supplies constant current or constant voltage to the electrode array 26), pulse duration (measured in microseconds), pulse rate (measured in pulses per second), and burst rate (measured as the modulation on duration X and modulation off duration Y).
Electrical modulation will occur between two (or more) activated electrodes, one of which may be the IPG case 44. Modulation energy may be transmitted to the tissue in a monopolar or multipolar (e.g., bipolar, tripolar, etc.) fashion. Monopolar modulation occurs when a selected one of the lead electrodes 26 is activated along with the case of the IPG 14, so that modulation energy is transmitted between the selected electrode 26 and case. Bipolar modulation occurs when two of the lead electrodes 26 are activated as anode and cathode, so that modulation energy is transmitted between the selected electrodes 26. For example, electrode E3 on the first lead 12(1) may be activated as an anode at the same time that electrode E11 on the second lead 12(1) is activated as a cathode. Tripolar modulation occurs when three of the lead electrodes 26 are activated, two as anodes and the remaining one as a cathode, or two as cathodes and the remaining one as an anode. For example, electrodes E4 and E5 on the first lead 12 may be activated as anodes at the same time that electrode E12 on the second lead 12 is activated as a cathode
The modulation energy may be delivered between a specified group of electrodes as monophasic electrical energy or multiphasic electrical energy. As illustrated in
Multiphasic electrical energy includes a series of pulses that alternate between positive and negative. For example, as illustrated in
The second phase may have an active charge recovery pulse (
Significant to the present inventions, the SCM system 10 is capable of allowing a user to define an electrical pulse parameter (e.g., a pulse amplitude, pulse rate, and/or a pulse duration) of an electrical pulse train that is to be modulated with a determinate modulation signal. The SCM system may also be capable of allowing a user to define the shape (e.g., sinusoidal, triangular, ramp, etc) of the modulation signal that is to be used to modulate the electrical pulse train. In this manner, more flexibility is provided to the user to tailor the pulsed electrical energy to the targeted volume of neural tissue to be modulated. Furthermore, for low- or mid-frequency applications (i.e., less than 1500 Hz), accommodation of the neural tissue may be prevented or otherwise minimized without having to expend a considerable amount of energy that might otherwise occur by utilizing high-frequency electrical energy. It is also proposed that the modulation of a low- or mid-frequency pulse train may desynchronize the firing of action potentials in the neural tissue at a reduced energy consumption.
The amplitude of a relatively high frequency electrical pulse train may be modulated by a relatively low frequency modulating signal to create an electrical pulse train having an envelope that varies in accordance with the amplitude of the modulating signal (i.e., as the amplitude of the modulating signal increases, the envelope of electrical pulse train increases, and as the amplitude of the modulating signal decreases, the envelope of the electrical pulse train decreases). For example, as illustrated in
The pulse rate of a relatively high frequency electrical pulse train may be modulated by a relatively low frequency modulating signal to create an electrical pulse train having a pulse rate that varies in accordance with the amplitude of the modulating signal (i.e., as the amplitude of the modulating signal increases, the pulse rate increases, and as the amplitude of the modulating signal decreases, the pulse rate decreases). For example, as illustrated in
The pulse duration of a relatively high frequency electrical pulse train may be modulated by a relatively low frequency modulating signal to create an electrical pulse train having a pulse duration that varies in accordance with the amplitude of the modulating signal (i.e., as the amplitude of the modulating signal increases, the pulse duration increases, and as the amplitude of the modulating signal decreases, the pulse duration decreases). For example, as illustrated in
Although the modulations of the electrical pulse trains illustrated above are biphasic in nature, it should be appreciated that the modulation of an electrical pulse train can be monophasic in nature; for example, by modulating the amplitudes of only the cathodic phases of the electrical pulse train.
Turning next to
Any of the N electrodes may be assigned to up to k possible groups or timing “channels.” In one embodiment, k may equal four. The timing channel identifies which electrodes are selected to synchronously source or sink current to create an electric field in the tissue to be stimulated. Amplitudes and polarities of electrodes on a channel may vary, e.g., as controlled by the RC 16. External programming software in the CP 18 is typically used to set neuromodulation parameters including electrode polarity, amplitude, pulse rate and pulse duration for the electrodes of a given channel, among other possible programmable features.
The N programmable electrodes can be programmed to have a positive (sourcing current), negative (sinking current), or off (no current) polarity in any of the k channels. Moreover, each of the N electrodes can operate in a multipolar (e.g., bipolar) mode, e.g., where two or more electrode contacts are grouped to source/sink current at the same time. Alternatively, each of the N electrodes can operate in a monopolar mode where, e.g., the electrode contacts associated with a channel are configured as cathodes (negative), and the case electrode (i.e., the IPG case) is configured as an anode (positive).
Further, the amplitude of the current pulse being sourced or sunk to or from a given electrode may be programmed to one of several discrete current levels, e.g., between 0 to 10 mA in steps of 0.1 mA. Also, the pulse duration of the current pulses is preferably adjustable in convenient increments, e.g., from 0 to 1 milliseconds (ms) in increments of 10 microseconds (μs). Similarly, the pulse rate is preferably adjustable within acceptable limits, e.g., from 0 to 50000 pulses per second (pps). Other programmable features can include slow start/end ramping, burst modulation cycling (on for X time, off for Y time), interphase, and open or closed loop sensing modes.
The operation of this neuromodulation output circuitry 50, including alternative embodiments of suitable output circuitry for performing the same function of generating modulation pulses of a prescribed amplitude and duration, is described more fully in U.S. Pat. Nos. 6,516,227 and 6,993,384, which are expressly incorporated herein by reference.
The IPG 14 further comprises pulse train modulation circuitry 60 configured for using predeterminate modulation signals (e.g., the modulating signals illustrated in
The IPG 14 further comprises monitoring circuitry 62 for monitoring the status of various nodes or other points 64 throughout the IPG 14, e.g., power supply voltages, temperature, battery voltage, and the like. The IPG 14 further comprises processing circuitry in the form of a microcontroller (μc) 66 that controls the control logic over data bus 68, and obtains status data from the monitoring circuitry 62 via data bus 70. The IPG 14 additionally controls the timer logic 56. The IPG 14 further comprises memory 72 and oscillator and clock circuitry 74 coupled to the microcontroller 66. The microcontroller 66, in combination with the memory 72 and oscillator and clock circuitry 74, thus comprise a microprocessor system that carries out a program function in accordance with a suitable program stored in the memory 72. Alternatively, for some applications, the function provided by the microprocessor system may be carried out by a suitable state machine.
Thus, the microcontroller 66 generates the necessary control and status signals, which allow the microcontroller 66 to control the operation of the IPG 14 in accordance with a selected operating program and neuromodulation parameters stored in the memory 72. In controlling the operation of the IPG 14, the microcontroller 66 is able to individually generate an electrical pulse train at the electrodes 26 using the neuromodulation output circuitry 50, in combination with the control logic 52 and timer logic 56, thereby allowing each electrode 26 to be paired or grouped with other electrodes 26, including the monopolar case electrode. In accordance with neuromodulation parameters stored within the memory 72, the microcontroller 66 may control the polarity, amplitude, rate, pulse duration and timing channel through which the modulation pulses are provided.
Thus, it can be appreciated that, under control of the microcontroller 66, the neuromodulation output circuitry 50 is configured for outputting a k number of individual electrical pulse trains respectively in a k number of timing channels to the electrical terminals 58. In the IPG 14, up to four stimulation programs may be stored in the memory 72, with each stimulation program having four timing channels. Thus, each modulation program defines four sets of neuromodulation parameters for four respective timing channels. Of course, the IPG 14 may have less or more than four modulation programs, and less or more than four timing channels for each modulation program. Significantly, the microcontroller 66 controls the modulation circuitry 60 in a manner that, for each timing channel, modulates the electrical pulse train in accordance with the electrical pulse parameter and/or shape of the modulating signal selected by the user.
The IPG 14 further comprises an alternating current (AC) receiving coil 76 for receiving programming data (e.g., the operating program, neuromodulation parameters, electrical parameters to be modulated, and/or the shape of the modulating signal) from the RC 16 (shown in
The IPG 14 further comprises back telemetry circuitry 60 and an alternating current (AC) transmission coil 82 for sending informational data sensed through the monitoring circuitry 62 to the RC 16. The back telemetry features of the IPG 14 also allow its status to be checked. For example, when the RC 16 initiates a programming session with the IPG 14, the capacity of the battery is telemetered, so that the external programmer can calculate the estimated time to recharge. Any changes made to the current stimulus parameters are confirmed through back telemetry, thereby assuring that such changes have been correctly received and implemented within the implant system. Moreover, upon interrogation by the RC 16, all programmable settings stored within the IPG 14 may be uploaded to the RC 16. Significantly, the back telemetry features allow raw or processed electrical parameter data (or other parameter data) previously stored in the memory 72 to be downloaded from the IPG 14 to the RC 16, which information can be used to track the physical activity of the patient.
The IPG 14 further comprises a rechargeable power source 84 and power circuits 86 for providing the operating power to the IPG 14. The rechargeable power source 84 may, e.g., comprise a lithium-ion or lithium-ion polymer battery. The rechargeable battery 84 provides an unregulated voltage to the power circuits 86. The power circuits 86, in turn, generate the various voltages 88, some of which are regulated and some of which are not, as needed by the various circuits located within the IPG 14. The rechargeable power source 84 is recharged using rectified AC power (or DC power converted from AC power through other means, e.g., efficient AC-to-DC converter circuits, also known as “inverter circuits”) received by the AC receiving coil 76. To recharge the power source 84, an external charger (not shown), which generates the AC magnetic field, is placed against, or otherwise adjacent, to the patient's skin over the implanted IPG 14. The AC magnetic field emitted by the external charger induces AC currents in the AC receiving coil 76. The charging and forward telemetry circuitry 78 rectifies the AC current to produce DC current, which is used to charge the power source 84. While the AC receiving coil 76 is described as being used for both wirelessly receiving communications (e.g., programming and control data) and charging energy from the external device, it should be appreciated that the AC receiving coil 76 can be arranged as a dedicated charging coil, while another coil, such as coil 82, can be used for bi-directional telemetry.
It should be noted that the diagram of
Additional details concerning the above-described and other IPGs may be found in U.S. Pat. No. 6,516,227, U.S. Patent Publication No. 2003/0139781, and U.S. patent application Ser. No. 11/138,632, entitled “Low Power Loss Current Digital-to-Analog Converter Used in an Implantable Pulse Generator,” which are expressly incorporated herein by reference. It should be noted that rather than an IPG, the SCM system 10 may alternatively utilize an implantable receiver-stimulator (not shown) connected to the neuromodulation leads 12. In this case, the power source, e.g., a battery, for powering the implanted receiver, as well as control circuitry to command the receiver-stimulator, will be contained in an external controller inductively coupled to the receiver-stimulator via an electromagnetic link. Data/power signals are transcutaneously coupled from a cable-connected transmission coil placed over the implanted receiver-stimulator. The implanted receiver-stimulator receives the signal and generates the modulation in accordance with the control signals.
Referring now to
In the illustrated embodiment, the button 106 serves as an ON/OFF button that can be actuated to turn the IPG 14 ON and OFF. The button 108 serves as a select button that allows the RC 106 to switch between screen displays and/or parameters. The buttons 110 and 112 serve as up/down buttons that can be actuated to increase or decrease any of stimulation parameters of the pulse generated by the IPG 14, including the pulse amplitude, pulse width, and pulse rate. For example, the selection button 108 can be actuated to place the RC 16 in a “Pulse Amplitude Adjustment Mode,” during which the pulse amplitude can be adjusted via the up/down buttons 110, 112, a “Pulse Width Adjustment Mode,” during which the pulse width can be adjusted via the up/down buttons 110, 112, and a “Pulse Rate Adjustment Mode,” during which the pulse rate can be adjusted via the up/down buttons 110, 112. Alternatively, dedicated up/down buttons can be provided for each stimulation parameter. Rather than using up/down buttons, any other type of actuator, such as a dial, slider bar, keypad, or touch screen can be used to increment or decrement the stimulation parameters.
The selection button 108 can also be actuated to place the RC 16 in an “pulse train modulation mode” that allows a user modulate the electrical pulse train output by the IPG 14 in one of the timing channels and to select the electrical pulse parameter to be modulated and/or the shape of the modulating signal. For example, referring to
Although the foregoing programming functions have been described as being at least partially implemented in the RC 16, it should be noted that these techniques may be at least, in part, be alternatively or additionally implemented in the CP 18. Those skilled in the art will be able to fashion appropriate circuitry, whether embodied in digital circuits, analog circuits, software and/or firmware, or combinations thereof, in order to accomplish the desired functions.
Although particular embodiments of the present inventions have been shown and described, it will be understood that it is not intended to limit the present inventions to the preferred embodiments, and it will be obvious to those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the present inventions. Thus, the present inventions are intended to cover alternatives, modifications, and equivalents, which may be included within the spirit and scope of the present inventions as defined by the claims.
The present application is a continuation of U.S. application Ser. No. 16/686,956, filed Nov. 18, 2019, which is a continuation of U.S. application Ser. No. 15/615,046, filed Jun. 6, 2017, now issued as U.S. Pat. No. 10,507,328, which is a continuation of U.S. application Ser. No. 15/426,776, filed Feb. 7, 2017, now issued as U.S. Pat. No. 10,118,040, which is a continuation of U.S. application Ser. No. 14/920,229, filed Oct. 22, 2015, now issued as U.S. Pat. No. 9,700,725, which is a continuation of U.S. application Ser. No. 14/195,632, filed Mar. 3, 2014, now issued as U.S. Pat. No. 9,174,053, which claims the benefit under 35 U.S.C. § 119 to U.S. provisional patent application Ser. No. 61/774,835, filed Mar. 8, 2013. The foregoing applications are hereby incorporated by reference into the present application in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4255790 | Hondeghem | Mar 1981 | A |
4338945 | Kosugi et al. | Jul 1982 | A |
4398537 | Holmbo | Aug 1983 | A |
4592359 | Galbraith | Jun 1986 | A |
4931858 | Honjo et al. | Jun 1990 | A |
4935674 | Rodriguez-cavazos | Jun 1990 | A |
5300096 | Hall et al. | Apr 1994 | A |
5360437 | Thompson | Nov 1994 | A |
5369224 | Miyata | Nov 1994 | A |
5381524 | Lewis et al. | Jan 1995 | A |
5576979 | Lewis et al. | Nov 1996 | A |
5603726 | Schulman et al. | Feb 1997 | A |
5713937 | Nappholz et al. | Feb 1998 | A |
5724985 | Snell et al. | Mar 1998 | A |
5725560 | Brink | Mar 1998 | A |
5782874 | Loos | Jul 1998 | A |
5938690 | Law et al. | Aug 1999 | A |
5941906 | Barreras, Sr. et al. | Aug 1999 | A |
6246912 | Sluijter et al. | Jun 2001 | B1 |
6266566 | Nichols et al. | Jul 2001 | B1 |
6289247 | Faltys et al. | Sep 2001 | B1 |
6516227 | Meadows et al. | Feb 2003 | B1 |
6675046 | Holsheimer | Jan 2004 | B2 |
6895280 | Meadows et al. | May 2005 | B2 |
6993384 | Bradley et al. | Jan 2006 | B2 |
7003349 | Andersson et al. | Feb 2006 | B1 |
7076307 | Boveja et al. | Jul 2006 | B2 |
7228179 | Van Campen et al. | Jun 2007 | B2 |
7317948 | King et al. | Jan 2008 | B1 |
7333856 | Er et al. | Feb 2008 | B1 |
7333857 | Campbell | Feb 2008 | B2 |
7539538 | Parramon et al. | May 2009 | B2 |
7627384 | Ayal et al. | Dec 2009 | B2 |
7650184 | Walter | Jan 2010 | B2 |
7664849 | Chandler et al. | Feb 2010 | B1 |
7783353 | Libbus et al. | Aug 2010 | B2 |
7826901 | Lee et al. | Nov 2010 | B2 |
7979119 | Kothandaraman et al. | Jul 2011 | B2 |
7979133 | Feler et al. | Jul 2011 | B2 |
7983762 | Gliner et al. | Jul 2011 | B2 |
7987000 | Moffitt et al. | Jul 2011 | B2 |
8010198 | Libbus et al. | Aug 2011 | B2 |
8019439 | Kuzma et al. | Sep 2011 | B2 |
8036754 | Lee et al. | Oct 2011 | B2 |
8160328 | Goetz et al. | Apr 2012 | B2 |
8170675 | Alataris et al. | May 2012 | B2 |
8175705 | Libbus | May 2012 | B2 |
8180129 | Goetz et al. | May 2012 | B2 |
8209021 | Alataris et al. | Jun 2012 | B2 |
8224453 | De Ridder | Jul 2012 | B2 |
8249711 | Libbus et al. | Aug 2012 | B2 |
8255057 | Fang et al. | Aug 2012 | B2 |
8285389 | Libbus et al. | Oct 2012 | B2 |
8340775 | Cullen et al. | Dec 2012 | B1 |
8355797 | Caparso et al. | Jan 2013 | B2 |
8359102 | Alataris et al. | Jan 2013 | B2 |
8359103 | Alataris et al. | Jan 2013 | B2 |
8380318 | Kishawi et al. | Feb 2013 | B2 |
8396559 | Alataris et al. | Mar 2013 | B2 |
8401653 | Libbus et al. | Mar 2013 | B2 |
8412345 | Moffitt | Apr 2013 | B2 |
8423147 | Alataris et al. | Apr 2013 | B2 |
8437857 | Moffitt et al. | May 2013 | B2 |
8455716 | Huang et al. | Jun 2013 | B2 |
8504147 | Deem et al. | Aug 2013 | B2 |
8560080 | Goetz | Oct 2013 | B2 |
8594785 | Bradely | Nov 2013 | B2 |
8615300 | Feler et al. | Dec 2013 | B2 |
8644947 | Zhu et al. | Feb 2014 | B2 |
8660653 | Kothandaraman | Feb 2014 | B2 |
8670831 | Wacnik et al. | Mar 2014 | B2 |
8676329 | Wacnik et al. | Mar 2014 | B2 |
8676331 | Parker | Mar 2014 | B2 |
8692843 | Bloemer | Apr 2014 | B2 |
8694104 | Libbus et al. | Apr 2014 | B2 |
8694113 | Smoorenburg | Apr 2014 | B2 |
8700178 | Anderson | Apr 2014 | B2 |
8706250 | Zhu et al. | Apr 2014 | B2 |
8731675 | Ranu et al. | May 2014 | B2 |
8751009 | Wacnik | Jun 2014 | B2 |
8788048 | Bennett et al. | Jul 2014 | B2 |
8788054 | Kothandaraman et al. | Jul 2014 | B2 |
8798755 | Grill et al. | Aug 2014 | B2 |
8874211 | Libbus et al. | Oct 2014 | B2 |
8649874 | Alataris et al. | Dec 2014 | B2 |
8909350 | Lee | Dec 2014 | B2 |
9138582 | Doan | Sep 2015 | B2 |
9174053 | Zhu | Nov 2015 | B2 |
9238138 | Lee et al. | Jan 2016 | B2 |
9265948 | Libbus et al. | Feb 2016 | B2 |
9339655 | Carbunaru | May 2016 | B2 |
9358391 | Zhu et al. | Jun 2016 | B2 |
9474905 | Doan et al. | Oct 2016 | B2 |
9700725 | Zhu | Jul 2017 | B2 |
9724513 | Lane et al. | Aug 2017 | B2 |
9737717 | Moffitt et al. | Aug 2017 | B2 |
9802052 | Marnfeldt | Oct 2017 | B2 |
9827422 | Zhu | Nov 2017 | B2 |
9950170 | Libbus et al. | Apr 2018 | B2 |
9981134 | Doan et al. | May 2018 | B2 |
10118036 | Zhu | Nov 2018 | B2 |
10118040 | Zhu | Nov 2018 | B2 |
10195439 | Steinke et al. | Feb 2019 | B2 |
10207109 | Zhu et al. | Feb 2019 | B2 |
10213608 | Moffitt | Feb 2019 | B2 |
10258797 | Zhu | Apr 2019 | B2 |
10335599 | Zottola | Jul 2019 | B2 |
10335601 | Wechter et al. | Jul 2019 | B2 |
10449360 | Moffitt et al. | Oct 2019 | B2 |
10456586 | Wechter et al. | Oct 2019 | B2 |
10507328 | Zhu | Dec 2019 | B2 |
10940314 | Zhu et al. | Mar 2021 | B2 |
11224750 | Zhu | Jan 2022 | B2 |
11684779 | Zhu | Jun 2023 | B2 |
20020077669 | Lindh et al. | Jun 2002 | A1 |
20020077859 | Stahmann et al. | Jun 2002 | A1 |
20020115939 | Mulligan et al. | Aug 2002 | A1 |
20020143365 | Herbst | Oct 2002 | A1 |
20030139781 | Bradley et al. | Jul 2003 | A1 |
20030176899 | Samuelsson et al. | Sep 2003 | A1 |
20030212440 | Boveja | Nov 2003 | A1 |
20040034394 | Woods et al. | Feb 2004 | A1 |
20040111131 | Hu et al. | Jun 2004 | A1 |
20040116978 | Bradley | Jun 2004 | A1 |
20040267333 | Kronberg | Dec 2004 | A1 |
20050060008 | Goetz | Mar 2005 | A1 |
20050177206 | North et al. | Aug 2005 | A1 |
20050267546 | Parramon et al. | Dec 2005 | A1 |
20060015153 | Gliner et al. | Jan 2006 | A1 |
20060149337 | John | Jul 2006 | A1 |
20060241720 | Woods et al. | Oct 2006 | A1 |
20060259078 | Libbus | Nov 2006 | A1 |
20070027486 | Armstrong | Feb 2007 | A1 |
20070142874 | John | Jun 2007 | A1 |
20070150036 | Anderson | Jun 2007 | A1 |
20070167991 | DiLorenzo | Jul 2007 | A1 |
20070168004 | Walter | Jul 2007 | A1 |
20070168007 | Kuzma et al. | Jul 2007 | A1 |
20070213783 | Pless | Sep 2007 | A1 |
20070225765 | King | Sep 2007 | A1 |
20070299663 | Fado et al. | Dec 2007 | A1 |
20080077192 | Harry et al. | Mar 2008 | A1 |
20080158175 | Hotelling et al. | Jul 2008 | A1 |
20080163097 | Goetz et al. | Jul 2008 | A1 |
20080188909 | Bradley | Aug 2008 | A1 |
20080243204 | Uthman et al. | Oct 2008 | A1 |
20090024189 | Lee et al. | Jan 2009 | A1 |
20090043359 | Smoorenburg | Feb 2009 | A1 |
20090118777 | Iki et al. | May 2009 | A1 |
20090196472 | Goetz et al. | Aug 2009 | A1 |
20090198305 | Naroditsky et al. | Aug 2009 | A1 |
20090198306 | Goetz et al. | Aug 2009 | A1 |
20090204173 | Fang et al. | Aug 2009 | A1 |
20100010390 | Skelton et al. | Jan 2010 | A1 |
20100010566 | Thacker et al. | Jan 2010 | A1 |
20100010646 | Drew et al. | Jan 2010 | A1 |
20100023090 | Jaax et al. | Jan 2010 | A1 |
20100114196 | Burnes et al. | May 2010 | A1 |
20100121409 | Kothandaraman et al. | May 2010 | A1 |
20100152817 | Gillbe | Jun 2010 | A1 |
20100249875 | Kishawi et al. | Sep 2010 | A1 |
20100274312 | Alataris et al. | Oct 2010 | A1 |
20100274314 | Alataris et al. | Oct 2010 | A1 |
20100274315 | Alataris et al. | Oct 2010 | A1 |
20100274316 | Alataris et al. | Oct 2010 | A1 |
20100274317 | Parker et al. | Oct 2010 | A1 |
20100274318 | Walker et al. | Oct 2010 | A1 |
20100274326 | Chitre et al. | Oct 2010 | A1 |
20100324630 | Lee et al. | Dec 2010 | A1 |
20110009923 | Lee | Jan 2011 | A1 |
20110040352 | Gerber et al. | Feb 2011 | A1 |
20110046697 | Gerber et al. | Feb 2011 | A1 |
20110054567 | Lane et al. | Mar 2011 | A1 |
20110054570 | Lane | Mar 2011 | A1 |
20110093051 | Davis et al. | Apr 2011 | A1 |
20110106214 | Carbunaru et al. | May 2011 | A1 |
20110125223 | Carbunaru et al. | May 2011 | A1 |
20110160810 | Griffith | Jun 2011 | A1 |
20110184486 | De Ridder | Jul 2011 | A1 |
20110184488 | De Ridder | Jul 2011 | A1 |
20110201977 | Tass | Aug 2011 | A1 |
20110208012 | Gerber et al. | Aug 2011 | A1 |
20110213440 | Fowler et al. | Sep 2011 | A1 |
20110213442 | Pless | Sep 2011 | A1 |
20110282414 | Kothandaraman et al. | Nov 2011 | A1 |
20110295332 | Osorio | Dec 2011 | A1 |
20120016437 | Alataris et al. | Jan 2012 | A1 |
20120059446 | Wallace et al. | Mar 2012 | A1 |
20120083709 | Parker et al. | Apr 2012 | A1 |
20120101547 | Jensen et al. | Apr 2012 | A1 |
20120109006 | James et al. | May 2012 | A1 |
20120184801 | Simon | Jul 2012 | A1 |
20120197336 | Su | Aug 2012 | A1 |
20120203304 | Alataris et al. | Aug 2012 | A1 |
20120215279 | Libbus | Aug 2012 | A1 |
20120253422 | Thacker et al. | Oct 2012 | A1 |
20120265267 | Blum et al. | Oct 2012 | A1 |
20120265279 | Zhu et al. | Oct 2012 | A1 |
20120283797 | De Ridder | Nov 2012 | A1 |
20120290041 | Kim et al. | Nov 2012 | A1 |
20120296395 | Hamann et al. | Nov 2012 | A1 |
20120296396 | Moffitt et al. | Nov 2012 | A1 |
20120302912 | Moffitt et al. | Nov 2012 | A1 |
20130018437 | De Ridder | Jan 2013 | A1 |
20130041283 | Wichner | Feb 2013 | A1 |
20130041425 | Fang et al. | Feb 2013 | A1 |
20130053926 | Hincapie Ordonez et al. | Feb 2013 | A1 |
20130060304 | Wichner | Feb 2013 | A1 |
20130066411 | Thacker et al. | Mar 2013 | A1 |
20130116752 | Parker et al. | May 2013 | A1 |
20130131760 | Rao et al. | May 2013 | A1 |
20130226261 | Sparks et al. | Aug 2013 | A1 |
20130268021 | Moffitt | Oct 2013 | A1 |
20130268026 | Rao et al. | Oct 2013 | A1 |
20130296975 | Lee et al. | Nov 2013 | A1 |
20130304152 | Bradley et al. | Nov 2013 | A1 |
20140005743 | Giuffrida et al. | Jan 2014 | A1 |
20140005744 | Hershey et al. | Jan 2014 | A1 |
20140005753 | Carbunaru | Jan 2014 | A1 |
20140031902 | Mashiach et al. | Jan 2014 | A1 |
20140046398 | Sachs et al. | Feb 2014 | A1 |
20140046407 | Ben-Ezra et al. | Feb 2014 | A1 |
20140052033 | Lawlis et al. | Feb 2014 | A1 |
20140067016 | Kaula et al. | Mar 2014 | A1 |
20140074179 | Heldman et al. | Mar 2014 | A1 |
20140074180 | Heldman et al. | Mar 2014 | A1 |
20140074190 | Griffith | Mar 2014 | A1 |
20140081349 | Lee et al. | Mar 2014 | A1 |
20140081354 | Davis et al. | Mar 2014 | A1 |
20140088674 | Bradley | Mar 2014 | A1 |
20140172045 | Yip et al. | Jun 2014 | A1 |
20140213926 | Vaidyanathan | Jul 2014 | A1 |
20140222100 | Libbus et al. | Aug 2014 | A1 |
20140222104 | Smith | Aug 2014 | A1 |
20140222113 | Gliner et al. | Aug 2014 | A1 |
20140243923 | Doan et al. | Aug 2014 | A1 |
20140243924 | Zhu et al. | Aug 2014 | A1 |
20140243925 | Kothandaraman | Aug 2014 | A1 |
20140257425 | Arcot-krishnamurthy et al. | Sep 2014 | A1 |
20140257428 | Zhu | Sep 2014 | A1 |
20140276181 | Sun et al. | Sep 2014 | A1 |
20140277267 | Vansickle et al. | Sep 2014 | A1 |
20140330345 | John | Nov 2014 | A1 |
20140364920 | Doan et al. | Dec 2014 | A1 |
20140364921 | Legay et al. | Dec 2014 | A1 |
20150012057 | Carlson et al. | Jan 2015 | A1 |
20150051666 | Roy et al. | Feb 2015 | A1 |
20150165209 | Grandhe et al. | Jun 2015 | A1 |
20150217117 | Hershey | Aug 2015 | A1 |
20150224307 | Bolea | Aug 2015 | A1 |
20150238762 | Pal et al. | Aug 2015 | A1 |
20150297893 | Kokones et al. | Oct 2015 | A1 |
20150328461 | Charlesworth et al. | Nov 2015 | A1 |
20150328462 | Griffith | Nov 2015 | A1 |
20150328467 | Demers et al. | Nov 2015 | A1 |
20150343242 | Tyler et al. | Dec 2015 | A1 |
20160001087 | Moffitt | Jan 2016 | A1 |
20160008604 | Doan et al. | Jan 2016 | A1 |
20160027293 | Esteller et al. | Jan 2016 | A1 |
20160074662 | Moffitt et al. | Mar 2016 | A1 |
20160074663 | De Ridder | Mar 2016 | A1 |
20160106985 | Zhu | Apr 2016 | A1 |
20160121126 | Marnfeldt | May 2016 | A1 |
20160129247 | Lee et al. | May 2016 | A1 |
20160243366 | Zhu et al. | Aug 2016 | A1 |
20160250472 | Carbunaru | Sep 2016 | A1 |
20160279422 | Libbus et al. | Sep 2016 | A1 |
20160279429 | Hershey et al. | Sep 2016 | A1 |
20160346546 | Zhu | Dec 2016 | A1 |
20170036030 | Doan et al. | Feb 2017 | A1 |
20170050033 | Wechter | Feb 2017 | A1 |
20170106197 | Wechter et al. | Apr 2017 | A1 |
20170143964 | Zhu | May 2017 | A1 |
20170266447 | Zhu | Sep 2017 | A1 |
20170304636 | Steinke et al. | Oct 2017 | A1 |
20170326365 | Lane et al. | Nov 2017 | A1 |
20170333718 | Moffitt et al. | Nov 2017 | A1 |
20180104488 | Zhu | Apr 2018 | A1 |
20190038901 | Zhu | Feb 2019 | A1 |
20190054306 | Steinke et al. | Feb 2019 | A1 |
20190126029 | Cheeran et al. | May 2019 | A1 |
20190160295 | Moffitt | May 2019 | A1 |
20190184169 | Zhu | Jun 2019 | A1 |
20190184180 | Zhang et al. | Jun 2019 | A1 |
20190262622 | Wechter | Aug 2019 | A1 |
20190329024 | Kothandaraman et al. | Oct 2019 | A1 |
20190366107 | Moffitt | Dec 2019 | A1 |
20200078593 | Zhu | Mar 2020 | A1 |
20200147397 | Huertas Fernandez et al. | May 2020 | A1 |
20210146138 | Zhu | May 2021 | A1 |
20210146139 | Zhu | May 2021 | A1 |
20220184400 | Zhu | Jun 2022 | A1 |
Number | Date | Country |
---|---|---|
2014218709 | May 2018 | AU |
2015318142 | Jun 2018 | AU |
2015343483 | Jun 2018 | AU |
2016297965 | Apr 2019 | AU |
2016268007 | Aug 2019 | AU |
2019203787 | Oct 2020 | AU |
2020289746 | Jan 2023 | AU |
1980610 | Jun 2007 | CN |
201139869 | Oct 2008 | CN |
101610735 | Dec 2009 | CN |
101687093 | Mar 2010 | CN |
102413870 | Apr 2012 | CN |
1956751 | Aug 2012 | CN |
102725023 | Oct 2012 | CN |
202933390 | May 2013 | CN |
203777499 | Aug 2014 | CN |
105163801 | Dec 2015 | CN |
105188838 | Apr 2017 | CN |
106687173 | May 2017 | CN |
107073269 | Aug 2017 | CN |
105163801 | Nov 2017 | CN |
107921255 | Apr 2018 | CN |
107921261 | Apr 2018 | CN |
108463266 | Aug 2018 | CN |
107073269 | May 2020 | CN |
107921261 | Jan 2022 | CN |
3328481 | May 2019 | EP |
3302690 | Sep 2019 | EP |
2449546 | Nov 2008 | GB |
1057508 | Mar 1998 | JP |
2004181100 | Jul 2004 | JP |
2006116332 | May 2006 | JP |
2010523215 | Jul 2010 | JP |
2010527675 | Aug 2010 | JP |
2010534114 | Nov 2010 | JP |
2013533092 | Aug 2013 | JP |
2014518722 | Aug 2014 | JP |
2015521532 | Jul 2015 | JP |
2016507334 | Mar 2016 | JP |
2016507335 | Mar 2016 | JP |
6163549 | Jun 2017 | JP |
2017527429 | Sep 2017 | JP |
2017533072 | Nov 2017 | JP |
6400028 | Sep 2018 | JP |
6452936 | Dec 2018 | JP |
WO-03051175 | Jun 2003 | WO |
WO-3051175 | Jun 2003 | WO |
WO-2006029257 | Mar 2006 | WO |
WO-2006135791 | Dec 2006 | WO |
WO-2008095185 | Aug 2008 | WO |
WO-2009067610 | May 2009 | WO |
WO-2011082071 | Jul 2011 | WO |
WO-2014130858 | Aug 2014 | WO |
WO-2014130865 | Aug 2014 | WO |
WO-2014159880 | Oct 2014 | WO |
WO-2014197596 | Dec 2014 | WO |
WO-2015119768 | Aug 2015 | WO |
WO-20150119768 | Aug 2015 | WO |
WO-2016004230 | Jan 2016 | WO |
WO-2016044169 | Mar 2016 | WO |
WO-2016073271 | May 2016 | WO |
WO-2016154375 | Sep 2016 | WO |
WO-2016172239 | Oct 2016 | WO |
WO-2016191055 | Dec 2016 | WO |
WO-2017019191 | Feb 2017 | WO |
WO-2017066187 | Apr 2017 | WO |
WO-2022132380 | Jun 2022 | WO |
Entry |
---|
““U.S. Appl. No. 15/818,186, Notice of Allowance mailed Jul. 5, 2018””, 8 pgs. |
“U.S. Appl. No. 14/195,632, Non Final Office Action mailed Mar. 18, 2015”, 6 pgs. |
“U.S. Appl. No. 14/195,632, Notice of Allowance mailed Jun. 26, 2015”, 5 pgs. |
“U.S. Appl. No. 14/195,632, Response filed Jun. 18, 2015 to Non Final Office Action mailed Mar. 18, 2015”, 10 pgs. |
“U.S. Appl. No. 14/600,649, Non Final Office Action mailed Oct. 1, 2015”, 12 pgs. |
“U.S. Appl. No. 14/600,649, Notice of Allowance mailed Mar. 7, 2016”, 8 pgs. |
“U.S. Appl. No. 14/600,649, Response filed Jan. 4, 2016 to Non Final Office Action mailed Oct. 1, 2015”, 8 pgs. |
“U.S. Appl. No. 14/920,229, Final Office Action mailed Aug. 16, 2016”, 8 pgs. |
“U.S. Appl. No. 14/920,229, Non Final Office Action mailed May 3, 2016”, 8 pgs. |
“U.S. Appl. No. 14/920,229, Notice of Allowability mailed Dec. 1, 2016”, 2 pgs. |
“U.S. Appl. No. 14/920,229, Notice of Allowance mailed Mar. 3, 2017”, 5 pgs. |
“U.S. Appl. No. 14/920,229, Notice of Allowance mailed Nov. 15, 2016”, 6 pgs. |
“U.S. Appl. No. 14/920,229, Preliminary Amendment filed Jan. 13, 2016”, 7 pgs. |
“U.S. Appl. No. 14/920,229, Response filed Aug. 3, 2016 to Non Final Office Action mailed May 3, 2016”, 8 pgs. |
“U.S. Appl. No. 15/146,145, Non Final Office Action mailed Jan. 11, 2017”, 7 pgs. |
“U.S. Appl. No. 15/146,145, Notice of Allowance mailed Jul. 28, 2017”, 8 pgs. |
“U.S. Appl. No. 15/146,145, Response filed Apr. 11, 2017 to Non Final Office Action mailed Jan. 11, 2017”, 9 pgs. |
“U.S. Appl. No. 15/426,776, Final Office Action mailed Apr. 17, 2018”, 5 pgs. |
“U.S. Appl. No. 15/426,776, Non Final Office Action mailed Dec. 29, 2017”, 7 pgs. |
“U.S. Appl. No. 15/426,776, Notice of Allowance mailed Jul. 6, 2018”, 5 pgs. |
“U.S. Appl. No. 15/426,776, Preliminary Amendment filed Feb. 8, 2017”, 7 pgs. |
“U.S. Appl. No. 15/426,776, Response filed Mar. 22, 2018 to Non Final Office Action mailed Dec. 29, 2017”, 9 pgs. |
“U.S. Appl. No. 15/426,776, Response filed Jun. 18, 2018 to Final Office Action mailed Apr. 17, 2018”, 7 pgs. |
“U.S. Appl. No. 15/615,046, Examiner Interview Summary mailed Mar. 22, 2019”, 3 pgs. |
“U.S. Appl. No. 15/615,046, Examiner Interview Summary mailed May 29, 2019”, 3 pgs. |
“U.S. Appl. No. 15/615,046, Final Office Action mailed Apr. 4, 2019”, 7 pgs. |
“U.S. Appl. No. 15/615,046, Non Final Office Action mailed Dec. 3, 2018”, 7 pgs. |
“U.S. Appl. No. 15/615,046, Notice of Allowance mailed Aug. 14, 2019”, 7 pgs. |
“U.S. Appl. No. 15/615,046, Preliminary Amendment filed Jun. 7, 2017”, 6 pgs. |
“U.S. Appl. No. 15/615,046, Response filed Jul. 3, 2019 to Final Office Action mailed Apr. 4, 2019”, 8 pgs. |
“U.S. Appl. No. 15/615,046. Non-Final Office Action Response Filed Mar. 21, 2019”, 15 pgs. |
“U.S. Appl. No. 15/818,186, Non Final Office Action mailed Feb. 13, 2018”, 7 pgs. |
“U.S. Appl. No. 15/818,186, Preliminary Amendment filed Jan. 8, 2018”, 7 pgs. |
“U.S. Appl. No. 15/818,186, Response filed May 7, 2018 to Non Final Office Action mailed Feb. 13, 2018”, 7 pgs. |
“U.S. Appl. No. 16/156,224, Notice of Allowance mailed Dec. 4, 2018, 7 pgs”. |
“U.S. Appl. No. 16/284,525, Non Final Office Action mailed Jul. 16, 2020”, 5 pgs. |
“U.S. Appl. No. 16/284,525, Notice of Allowance mailed Nov. 2, 2020”, 7 pgs. |
“U.S. Appl. No. 16/284,525, Response filed Sep. 29, 2020 to Non Final Office Action mailed Jul. 16, 2020”, 6 pgs. |
“U.S. Appl. No. 16/686,956, Non Final Office Action mailed May 18, 2021”, 8 pgs. |
“U.S. Appl. No. 16/686,956, Notice of Allowance mailed Sep. 13, 2021”, 5 pgs. |
“U.S. Appl. No. 16/686,956, Preliminary Amendment Filed Nov. 20, 2019”, 6 pgs. |
“U.S. Appl. No. 16/686,956, Response filed Aug. 2, 2021 to Non Final Office Action mailed May 18, 2021”, 8 pgs. |
“U.S. Appl. No. 14/920,229, Response filed Oct. 17, 2016 to Final Office Action mailed Aug. 16, 2016”, 10 pgs. |
“Australian Application Serial No. 2016268007, First Examination Report mailed Apr. 5, 2018”, 3 pgs. |
“Australian Application Serial No. 2016268007, Response filed Mar. 25, 2019 to First Examination Report mailed Apr. 5, 2018”, 15 pgs. |
“Australian Application Serial No. 2019203787, First Examination Report mailed Nov. 29, 2019”, 3 pgs. |
“Australian Application Serial No. 2019203787, Response filed Sep. 11, 2020 to First Examination Report mailed Nov. 29, 2019”, no amendments were made, no arguments, only postponement of acceptance withdrawn., 1 pg. |
“Chinese Application Serial No. 201680042569.1, Office Action mailed Sep. 2, 2020”, w/ English translation, 19 pgs. |
“Chinese Application Serial No. 201680042569.1, Response filed Jan. 8, 2021 to Office Action mailed Sep. 2, 2020”, w/ English Claims, 4 pgs. |
“European Application Serial No. 16725275.8, Response filed Aug. 29, 2018 to Communication Pursuant to Rules 161 and 162 EPC mailed Feb. 27, 2018”, 30 pgs. |
“International Application Serial No. PCT/US2015/012030, International Search Report mailed Apr. 21, 2015”, 5 pgs. |
“International Application Serial No. PCT/US2015/012030, Written Opinion mailed Apr. 21, 2015”, 7 pgs. |
“International Application Serial No. PCT/US2016/030686, International Preliminary Report on Patentability mailed Dec. 7, 2017”, 8 pgs. |
“International Application Serial No. PCT/US2016/030686, International Search Report mailed Jul. 25, 2016”, 4 pgs. |
“International Application Serial No. PCT/US2016/030686, Written Opinion mailed Jul. 25, 2016”, 6 pgs. |
Warman, Eduardo N., et al., “Modeling the Effects of Electric Fields on Nerve Fibers: Determination of Excitation Thresholds”, IEEE Transactions on Biomedical Engineering, vol. 39, No. 12, Dec. 1992, (Dec. 1992). |
U.S. Appl. No. 14/195,632 U.S. Pat. No. 9,174,053, filed Mar. 3, 2014, Neuromodulation Using Modulated Pulse Train. |
U.S. Appl. No. 14/920,229 U.S. Pat. No. 9,700,725, filed Oct. 22, 2015, Neuromodulation Using Modulated Pulse Train. |
U.S. Appl. No. 15/426,776 U.S. Pat. No. 10,118,040, filed Feb. 7, 2017, Neuromodulation Using Modulated Pulse Train. |
U.S. Appl. No. 15/615,046 U.S. Pat. No. 10,507,328, filed Jun. 6, 2017, Neuromodulation Using Modulated Pulse Train. |
U.S. Appl. No. 16/686,956, filed Nov. 18, 2019, Neuromodulation Using Modulated Pulse Train. |
U.S. Appl. No. 15/146,145 U.S. Pat. No. 9,827,422. filed May 4, 2016, Neuromodulation Using Stochastically-Modulated Stimulation Parameters. |
U.S. Appl. No. 15/818,186 U.S. Pat. No. 10,118,036, filed Nov. 20, 2017, Neuromodulation Using Stochastically-Modulated Stimulation Parameters. |
U.S. Appl. No. 16/156,224 U.S. Pat. No. 10,258,797, filed Oct. 10, 2018, Neuromodulation Using Stochastically-Modulated Stimulation Parameters. |
U.S. Appl. No. 16/284,525 U.S. Pat. No. 10,940,314, filed Feb. 25, 2019, Neuromodulation Using Stochastically-Modulated Stimulation Parameters. |
U.S. Appl. No. 17/157,659, filed Jan. 25, 2021, Neuromodulation Using Stochastically-Modulated Stimulation Parameters. |
U.S. Appl. No. 17/157,690, filed Jan. 25, 2021, Neuromodulation Using Stochastically-Modulated Stimulation Parameters. |
“U.S. Appl. No. 14/186,885, Non Final Office Action mailed Feb. 4, 2015”, 9 pgs. |
“U.S. Appl. No. 14/186,885, Notice of Allowance mailed May 22, 2015”, 10 pgs. |
“U.S. Appl. No. 14/186,885, Response filed May 4, 2015 to Non Final Office Action mailed Feb. 4, 2015”, 8 pgs. |
“U.S. Appl. No. 14/186,927, Final Office Action mailed Nov. 20, 2015”, 5 pgs. |
“U.S. Appl. No. 14/186,927, Non Final Office Action mailed May 5, 2015”, 7 pgs. |
“U.S. Appl. No. 14/186,927, Response filed Jan. 20, 2016 to Final Office Action mailed Nov. 20, 2015”, 8 pgs. |
“U.S. Appl. No. 14/186,927, Response filed Aug. 4, 2015 to Non Final Office Action maield May 5, 2015”, 10 pgs. |
“U.S. Appl. No. 14/853,589, Final Office Action mailed Jan. 18, 2017”, 12 pgs. |
“U.S. Appl. No. 14/853,589, Non Final Office Action mailed Aug. 17, 2016”, 14 pgs. |
“U.S. Appl. No. 14/853,589, Notice of Allowance mailed Apr. 17, 2017”, 5 pgs. |
“U.S. Appl. No. 14/853,589, Response filed Mar. 14, 2017 to Final Office Action mailed Jan. 18, 2017”, 12 pgs. |
“U.S. Appl. No. 14/853,589, Response filed Nov. 17, 2016 to Non Final Office Action mailed Aug. 17, 2016”, 12 pgs. |
“U.S. Appl. No. 14/859,456, Non Final Office Action mailed Feb. 1, 2016”, 9 pgs. |
“U.S. Appl. No. 14/859,456, Notice of Allowance mailed Jun. 22, 2016”, 7 pgs. |
“U.S. Appl. No. 14/859,456, Preliminary Amendment filed Oct. 21, 2015”, 6 pgs. |
“U.S. Appl. No. 14/859,456, Response filed May 2, 2016 to Non Final Office Action mailed Feb. 1, 2016”, 10 pgs. |
“U.S. Appl. No. 14/926,725, Corrected Notice of Allowance mailed Jul. 17, 2017”, 2 pgs. |
“U.S. Appl. No. 14/926,725, Non Final Office Action mailed Mar. 3, 2017”, 13 pgs. |
“U.S. Appl. No. 14/926,725, Notice of Allowability mailed Jul. 28, 2017”, 2 pgs. |
“U.S. Appl. No. 14/926,725, Notice of Allowance mailed Jun. 27, 2017”, 8 pgs. |
“U.S. Appl. No. 14/926,725, Response filed May 25, 2017 to Non Final Office Action mailed Mar. 3, 2017”, 12 pgs. |
“U.S. Appl. No. 15/079,340, Advisory Action mailed Apr. 8, 2019”, 3 pgs. |
“U.S. Appl. No. 15/079,340, Advisory Action mailed Jun. 21, 2018”, 3 pgs. |
“U.S. Appl. No. 15/079,340, Examiner Interview Summary mailed Mar. 5, 2019”, 3 pgs. |
“U.S. Appl. No. 15/079,340, Examiner Interview Summary mailed Jun. 17, 2019”, 3 pgs. |
“U.S. Appl. No. 15/079,340, Final Office Action mailed Jan. 10, 2019”, 13 pgs. |
“U.S. Appl. No. 15/079,340, Final Office Action mailed Apr. 4, 2018”, 12 pgs. |
“U.S. Appl. No. 15/079,340, Non Final Office Action mailed May 13, 2019”, 13 pgs. |
“U.S. Appl. No. 15/079,340, Non Final Office Action mailed Jul. 27, 2018”, 12 pgs. |
“U.S. Appl. No. 15/079,340, Non Final Office Action mailed Oct. 3, 2017”, 10 pgs. |
“U.S. Appl. No. 15/079,340, Response filed Mar. 4, 2019 to Final Office Action mailed Jan. 10, 2019”, 12 pgs. |
“U.S. Appl. No. 15/079,340, Response filed Jun. 4, 2018 to Final Office Action mailed Apr. 4, 2018”, 10 pgs. |
“U.S. Appl. No. 15/079,340, Response filed Oct. 29, 2018 to Non Final Office Action mailed Jul. 27, 2018”, 10 pgs. |
“U.S. Appl. No. 15/079,340, Response filed Dec. 20, 2017 to Non Final Office Action mailed Oct. 3, 2017”, 10 pgs. |
“U.S. Appl. No. 15/079,340, Supplemental Amendment and Response Apr. 10, 2019”, 14 pgs. |
“U.S. Appl. No. 15/145,425, Response filed Mar. 22, 2018 to Non Final Office Aciton mailed Dec. 26, 2017”, 10 pgs. |
“U.S. Appl. No. 15/145,425, Advisory Action mailed Nov. 6, 2017”, 3 pgs. |
“U.S. Appl. No. 15/145,425, Examiner Interview Summary mailed Mar. 29, 2018”, 4 pgs. |
“U.S. Appl. No. 15/145,425, Examiner Interview Summary mailed Sep. 18, 2018”, 3 pgs. |
“U.S. Appl. No. 15/145,425, Final Office Action mailed Jul. 20, 2018”, 9 pgs. |
“U.S. Appl. No. 15/145,425, Final Office Action mailed Jul. 26, 2017”, 9 pgs. |
“U.S. Appl. No. 15/145,425, Non Final Office Action mailed Jan. 13, 2017”, 11 pgs. |
“U.S. Appl. No. 15/145,425, Non Final Office Action mailed Dec. 26, 2017”, 8 pgs. |
“U.S. Appl. No. 15/145,425, Notice of Allowance mailed Oct. 15, 2018”, 8 pgs. |
“U.S. Appl. No. 15/145,425, Preliminary Amendment filed May 4, 2016”, 7 pgs. |
“U.S. Appl. No. 15/145,425, Response filed Apr. 12, 2017 to Non Final Office Action mailed Jan. 13, 2017”, 10 pgs. |
“U.S. Appl. No. 15/145,425, Response filed Sep. 19, 2018 to Final Office Action mailed Jul. 20, 2018”, 9 pgs. |
“U.S. Appl. No. 15/145,425, Response filed Sep. 26, 2017 to Final Office Action mailed Jul. 26, 2017”, 9 pgs. |
“U.S. Appl. No. 15/149,662, Advisory Action mailed Jan. 29, 2018”, 3 pgs. |
“U.S. Appl. No. 15/149,662, Final Office Action mailed Nov. 24, 2017”, 11 pgs. |
“U.S. Appl. No. 15/149,662, Non Final Office Action mailed Apr. 19, 2017”, 11 pgs. |
“U.S. Appl. No. 15/149,662, Response filed Jan. 16, 2018 to Final Office Action mailed Nov. 24, 2017”, 19 pgs. |
“U.S. Appl. No. 15/149,662, Response filed Aug. 21, 2017 to Non Final Office Action mailed Apr. 19, 2017”, 14 pgs. |
“U.S. Appl. No. 15/180,980, Advisory Action mailed May 24, 2018”, 5 pgs. |
“U.S. Appl. No. 15/180,980, Examiner Interview Summary mailed Apr. 30, 2018”, 3 pgs. |
“U.S. Appl. No. 15/180,980, Examiner Interview Summary mailed Oct. 10, 2018”, 3 pgs. |
“U.S. Appl. No. 15/180,980, Final Office Action mailed Mar. 1, 2018”, 10 pgs. |
“U.S. Appl. No. 15/180,980, Non Final Office Action mailed Jul. 19, 2018”, 10 pgs. |
“U.S. Appl. No. 15/180,980, Non Final Office Action mailed Sep. 21, 2017”, 9 pgs. |
“U.S. Appl. No. 15/180,980, Repsonse filed Dec. 20, 2017 to Non Final Office Action mailed Sep. 21, 2017”, 15 pgs. |
“U.S. Appl. No. 15/180,980, Response filed Jul. 2, 2018 to Advisory Action mailed May 24, 2018”, 11 pgs. |
“U.S. Appl. No. 15/180,980, Response filed Oct. 8, 2018 to Non Final Office Action mailed Jul. 19, 2018”, 12 pgs. |
“U.S. Appl. No. 15/290,776, Examiner Interview Summary mailed Oct. 12, 2018”, 3 pgs. |
“U.S. Appl. No. 15/290,776, Non Final Office Action mailed Jul. 12, 2018”, 18 pgs. |
“U.S. Appl. No. 15/290,776, Notice of Allowance mailed Apr. 24, 2019”, 8 pgs. |
“U.S. Appl. No. 15/290,776, Response filed Oct. 8, 2018 to Non Final Office Action mailed Jul. 12, 2018”, 11 pgs. |
“U.S. Appl. No. 15/290,776, Response filed Mar. 19, 2019 to Final Office Action mailed Jan. 31, 2019”, 8 pgs. |
“U.S. Appl. No. 15/331,473, Non Final Office Action mailed Aug. 9, 2017”, 7 pgs. |
“U.S. Appl. No. 15/331,473, Notice of Allowance mailed Feb. 1, 2018”, 7 pgs. |
“U.S. Appl. No. 15/331,473, Preliminary Amendment filed Nov. 7, 2016”, 7 pgs. |
“U.S. Appl. No. 15/331,473, Response filed Nov. 8, 2017 to Non Final Office Action mailed Aug. 9, 2017”, 8 pgs. |
“U.S. Appl. No. 15/667,891, Preliminary Amendment filed Aug. 11, 2017”, 7 pgs. |
“U.S. Appl. No. 15/670,328, Non Final Office Action mailed Apr. 24, 2019”, 7 pgs. |
“U.S. Appl. No. 15/670,328, Notice of Allowance mailed Jun. 11, 2019”, 6 pgs. |
“U.S. Appl. No. 15/670,328, Response filed Apr. 9, 2019 to Non Final Office Action mailed Jan. 14, 2019”, 11 pgs. |
“U.S. Appl. No. 15/670,328, Response filed May 23, 2019 to Non Final Office Action mailed Apr. 24, 2019”, 8 Pgs. |
“U.S. Appl. No. 17/157,659, Non Final Office Action mailed Dec. 1, 2023”, 14 pgs. |
“U.S. Appl. No. 17/157,659, Preliminary Amendment filed Nov. 1, 2022”, 7 pgs. |
“U.S. Appl. No. 17/157,659, Response filed Feb. 22, 2024 to Non Final Office Action mailed Dec. 1, 2023”, 10 pgs. |
“U.S. Appl. No. 17/157,659, Response filed Sep. 19, 2023 to Restriction Requirement mailed Jul. 28, 2023”, 6 pgs. |
“U.S. Appl. No. 17/157,659, Restriction Requirement mailed Jul. 28, 2023”, 7 pgs. |
“U.S. Appl. No. 17/157,690, Non Final Office Action mailed Oct. 7, 2022”, 5 pgs. |
“U.S. Appl. No. 17/157,690, Notice of Allowance mailed Feb. 21, 2023”, 8 pgs. |
“U.S. Appl. No. 17/157,690, Resp onse filed Jan. 6, 2022 to Non Final Office Action mailed Oct. 7, 2022”, 6 pgs. |
“U.S. Appl. No. 14/186,927, Notice of Allowance mailed Feb. 10, 2016”, 8 pgs. |
“Australian Application Serial No. 2014218709, First Examiner Report mailed Jul. 31, 2017”, 3 pgs. |
“Australian Application Serial No. 2014218709, Response filed Mar. 29, 2018 to First Examiner Report mailed Jul. 31, 2017”, 13 pgs. |
“Australian Application Serial No. 2014218716, First Examiners Report mailed Aug. 4, 2017”, 2 pgs. |
“Australian Application Serial No. 2014218716, Response filed Sep. 6, 2017 to First Examiners Report mailed Aug. 4, 2017”, 8 pgs. |
“Australian Application Serial No. 2015318142, First Examiners Report mailed Sep. 15, 2017”, 3 pgs. |
“Australian Application Serial No. 2015318142, Response filed Feb. 8, 2018 to First Examiners Report mailed Sep. 15, 2017”, 15 pgs. |
“Australian Application Serial No. 2015343483, First Examiners Report mailed Sep. 19, 2017”, 3 pgs. |
“Australian Application Serial No. 2015343483, Response filed Feb. 8, 2018 to First Examiners Report mailed Sep. 19, 2017”, 17 pgs. |
“Australian Application Serial No. 2016297965, First Examination Report mailed Jun. 19, 2018”, 3 pgs. |
“Australian Application Serial No. 2016297965, Response filed Feb. 22, 2019 to First Examination Report mailed Jun. 19, 2018”, 13 pgs. |
“Australian Application Serial No. 2020289746, First Examination Report mailed Mar. 11, 2022”, 4 pgs. |
“Australian Application Serial No. 2020289746, Response filled Nov. 17, 2022 to First Examination Report mailed Mar. 11, 2022”, 6 pgs. |
“Chinese Application Serial No. 201480023455.3, Office Action mailed Apr. 19, 2017”, with English translation, 7 pages. |
“Chinese Application Serial No. 201480023455.3, Office Action mailed Sep. 2, 2016”, with English translation, 13 pages. |
“Chinese Application Serial No. 201480023455.3, Response filed Jan. 12, 2017 to Office Action mailed Sep. 2, 2016”, with English claims, 10 pages. |
“Chinese Application Serial No. 201480023455.3, Response filed Jun. 21, 2017 to Office Action mailed Apr. 19, 2017”, with English claims, 8 pages. |
“Chinese Application Serial No. 201480023467.6, Office Action mailed Aug. 9, 2016”, with machine English translation, 11 pages. |
“Chinese Application Serial No. 201480023467.6, Response filed Dec. 19, 2016 to Office Action mailed Aug. 9, 2016”, with English claims, 117 pages. |
“Chinese Application Serial No. 201580048568.3, Office Action mailed Mar. 28, 2019”, with English translation, 26 pages. |
“Chinese Application Serial No. 201580048568.3, Office Action mailed Jul. 31, 2018”, with English translation, 24 pages. |
“Chinese Application Serial No. 201580060184.3, Office Action mailed Aug. 2, 2019”, with English translation, 12 pages. |
“Chinese Application Serial No. 201580060184.3, Response filed Oct. 9, 2019 to Office Action mailed Aug. 2, 2019”, with English claims, 14 pages. |
“Chinese Application Serial No. 201580060184.3, Response to Examiner Telephone Interview filed Jan. 7, 2020”, with English claims, 13 pages. |
“Chinese Application Serial No. 201680042569.1, Office Action mailed May 8, 2021”, with English translation, 14 pages. |
“Chinese Application Serial No. 201680042569.1, Response filed Jun. 28, 2021 to Office Action mailed May 8, 2021”, with English claims, 51 pages. |
“European Application Serial No. 13739318.7, Communication Pursuant to Article 94(3) EPC mailed Apr. 6, 2017”, 4 pgs. |
“European Application Serial No. 13739318.7, Response filed Aug. 9, 2017 to Communication Pursuant to Article 94(3) EPC mailed Apr. 6, 2017”, 7 pgs. |
“European Application Serial No. 14709103.7, Communication Pursuant to Article 94(3) EPC mailed Sep. 4, 2019”, 6 pgs. |
“European Application Serial No. 14709103.7, Response filed Jan. 13, 2020 to Communication Pursuant to Article 94(3) EPC mailed Sep. 4, 2019”, 10 pgs. |
“European Application Serial No. 15767069.6, Response filed Nov. 23, 2017 to Communication Pursuant to Rules 161 and 162 EPC mailed May 19, 2017”, 12 pgs. |
“European Application Serial No. 15791183.5, Response filed Feb. 6, 2018 to Communication Pursuant to Rules 161 & 162 EPC mailed Jul. 27, 2017”, 12 pgs. |
“European Application Serial No. 16732137.1, Response filed Oct. 15, 2018 to Communication Pursuant to Rules 161 and 162 EPC mailed Apr. 3, 2018”, 10 pgs. |
“European Application Serial No. 18201843.2, Response filed Sep. 25, 2019 to Extended European Search Report mailed Jan. 2, 2019”, 10 pgs. |
“International Application Serial No. PCT/US15/58017, International Search Report mailed Apr. 6, 2016”, 5 pgs. |
“International Application Serial No. PCT/US15/58017, Written Opinion mailed Apr. 6, 2016”, 8 pgs. |
“International Application Serial No. PCT/US2014/017777, International Preliminary Report on Patentability mailed Sep. 3, 2015”, 9 pgs. |
“International Application Serial No. PCT/US2014/017777, International Search Report mailed May 13, 2014”, 6 pgs. |
“International Application Serial No. PCT/US2014/017777, Written Opinion mailed May 13, 2014”, 7 pgs. |
“International Application Serial No. PCT/US2014/017789, International Preliminary Report on Patentability mailed Sep. 3, 2015”, 7 pgs. |
“International Application Serial No. PCT/US2014/017789, International Search Report mailed May 22, 2014”, 3 pgs. |
“International Application Serial No. PCT/US2014/017789, Written Opinion mailed May 22, 2014”, 5 pgs. |
“International Application Serial No. PCT/US2015/049993, International Preliminary Report on Patentability mailed Mar. 30, 2017”, 6 pgs. |
“International Application Serial No. PCT/US2015/049993, International Search Report mailed Jan. 14, 2016”, 3 pgs. |
“International Application Serial No. PCT/US2015/049993, Written Opinion mailed Jan. 14, 2016”, 4 pgs. |
“International Application Serial No. PCT/US2015/058017, International Preliminary Report on Patentability mailed May 18, 2017”, 10 pgs. |
“International Application Serial No. PCT/US2016/023888, International Preliminary Report on Patentability mailed Oct. 5, 2017”, 7 pgs. |
“International Application Serial No. PCT/US2016/023888, International Search Report mailed Jun. 6, 2016”, 5 pgs. |
“International Application Serial No. PCT/US2016/023888, Written Opinion mailed Jun. 6, 2016”, 5 pgs. |
“International Application Serial No. PCT/US2016/037226, International Preliminary Report on Patentability mailed Feb. 8, 2018”, 7 pgs. |
“International Application Serial No. PCT/US2016/037226, International Search Report mailed Aug. 25, 2016”, 4 pgs. |
“International Application Serial No. PCT/US2016/037226, Written Opinion mailed Aug. 25, 2016”, 5 pgs. |
“International Application Serial No. PCT/US2016/056426, International Preliminary Report on Patentability mailed Apr. 26, 2018”, 8 pgs. |
“International Application Serial No. PCT/US2016/056426, International Search Report mailed Jan. 26, 2017”, 5 pgs. |
“International Application Serial No. PCT/US2016/056426, Written Opinion mailed Jan. 26, 2017”, 6 pgs. |
“International Application Serial No. PCT/US2021/059948, International Preliminary Report on Patentability mailed Jun. 29, 2023”, 10 pgs. |
“International Application Serial No. PCT/US2021/059948, International Search Report mailed Mar. 3, 2022”, 5 pgs. |
“International Application Serial No. PCT/US2021/059948, Written Opinion mailed Mar. 3, 2022”, 8 pgs. |
“Japanese Application Serial No. 2015-559010, Examiners Decision of Final Refusal mailed Aug. 6, 2018”, with English translation, 6 pages. |
“Japanese Application Serial No. 2015-559010, Office Action mailed Nov. 27, 2017”, with English translation, 6 pages. |
“Japanese Application Serial No. 2015-559010, Response filed Feb. 27, 2018 to Office Action mailed Nov. 27, 2017”, with English claims, 7 pages. |
“Japanese Application Serial No. 2015-559013, Office Action mailed Dec. 11, 2017”, with English translation, 5 pages. |
“Japanese Application Serial No. 2015-559013, Response filed Mar. 9, 2018 to Office Action mailed Dec. 11, 2017”, with English claims, 8 pages. |
“Japanese Application Serial No. 2017-533728, Office Action mailed Jan. 11, 2018”, with partial English translation, 8 pages. |
“Japanese Application Serial No. 2017-542797, Office Action mailed May 21, 2018”, with English translation, 7 pages. |
“Japanese Application Serial No. 2017-542797, Response filed Aug. 17, 2018 to Office Action mailed May 21, 2018”, with English claims, 9 pages. |
Carlson, Dave, et al., “A Flexible Algorithm Framework for Closed-Loop Neuromodulation Research Systems”, Annual International Conference of the IEEE EMBS, (2013), 6146-6150. |
Huiling, Zhao, et al., “A new type of intelligent electric stimulation”, Chinese Medical Equipment, vol. 8, Issue 10, (Oct. 31, 2011), 1-4. |
Que, Doan T, et al., “Multi-Channel Neuromodulation System Having Frequency Modulation Stimulation”, U.S. Appl. No. 61/768,286, filed Feb. 22, 2013, 46 pages. |
Rao, Prakash, et al., “Technique for Linking Electrodes Together During Programming of Neurostimulation System”, U.S. Appl. No. 61/561,760, filed Nov. 18, 2011, 62 pages. |
VanSickle, Dennis Allen, et al., “Neuromodulation System and Method for Transitioning Between Programming Modes”, U.S. Appl. No. 14/214,752, filed Mar. 15, 2014, 159 pgs. |
VanSickle, Dennis Allen, “Systems and Methods for Delivering Sub-Threshold Therapy to a Patient”, U.S. Appl. No. 61/801,917, filed Mar. 15, 2013, 124 pages. |
Number | Date | Country | |
---|---|---|---|
20220118260 A1 | Apr 2022 | US |
Number | Date | Country | |
---|---|---|---|
61774835 | Mar 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16686956 | Nov 2019 | US |
Child | 17562865 | US | |
Parent | 15615046 | Jun 2017 | US |
Child | 16686956 | US | |
Parent | 15426776 | Feb 2017 | US |
Child | 15615046 | US | |
Parent | 14920229 | Oct 2015 | US |
Child | 15426776 | US | |
Parent | 14195632 | Mar 2014 | US |
Child | 14920229 | US |